- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00334152
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
21. mars 2017 oppdatert av: GlaxoSmithKline
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
515
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Aalst, Belgia, 9300
- GSK Investigational Site
-
Brasschaat, Belgia, 2930
- GSK Investigational Site
-
Bruxelles, Belgia, 1200
- GSK Investigational Site
-
Gent, Belgia, 9000
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 1X5
- GSK Investigational Site
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 4G2
- GSK Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 5N4
- GSK Investigational Site
-
-
-
-
-
Moscow, Den russiske føderasjonen, 101000
- GSK Investigational Site
-
Moscow, Den russiske føderasjonen, 111538
- GSK Investigational Site
-
Moscow, Den russiske føderasjonen, 117152
- GSK Investigational Site
-
Perm, Den russiske føderasjonen, 614107
- GSK Investigational Site
-
St. Petersburgh, Den russiske føderasjonen, 192242
- GSK Investigational Site
-
-
-
-
-
Manila, Filippinene, 1000
- GSK Investigational Site
-
Quezon, City, Filippinene, 1104
- GSK Investigational Site
-
-
-
-
Alabama
-
Fairhope, Alabama, Forente stater, 36532
- GSK Investigational Site
-
Mobile, Alabama, Forente stater, 36608
- GSK Investigational Site
-
Montgomery, Alabama, Forente stater, 36106
- GSK Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- GSK Investigational Site
-
-
California
-
Arcadia, California, Forente stater, 91007
- GSK Investigational Site
-
Glendale, California, Forente stater, 91206
- GSK Investigational Site
-
Laguna Hills, California, Forente stater, 92653
- GSK Investigational Site
-
Pasadena, California, Forente stater, 91105
- GSK Investigational Site
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33067
- GSK Investigational Site
-
Melbourne, Florida, Forente stater, 32901
- GSK Investigational Site
-
Miami, Florida, Forente stater, 33143
- GSK Investigational Site
-
West Palm Beach, Florida, Forente stater, 33409
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- GSK Investigational Site
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- GSK Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21229-5299
- GSK Investigational Site
-
-
Michigan
-
Royal Oak, Michigan, Forente stater, 48073
- GSK Investigational Site
-
-
New York
-
Mineola, New York, Forente stater, 11501
- GSK Investigational Site
-
New Hyde Park, New York, Forente stater, 11040
- GSK Investigational Site
-
New York, New York, Forente stater, 10038
- GSK Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27103
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45208
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- GSK Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22908
- GSK Investigational Site
-
Winchester, Virginia, Forente stater, 22601
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, Forente stater, 98195
- GSK Investigational Site
-
-
-
-
-
Kwun Tong, Hong Kong
- GSK Investigational Site
-
Pokfulam, Hong Kong
- GSK Investigational Site
-
Shatin, New Territories, Hong Kong
- GSK Investigational Site
-
Sheung Shui, New Territories, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Lahore, Pakistan
- GSK Investigational Site
-
-
-
-
-
Badalona, Spania, 08916
- GSK Investigational Site
-
Barcelona, Spania, 08025
- GSK Investigational Site
-
Barcelona, Spania, 08035
- GSK Investigational Site
-
Barcelona, Spania, 08003
- GSK Investigational Site
-
La Coruña, Spania, 15006
- GSK Investigational Site
-
Mataro, Spania, 08034
- GSK Investigational Site
-
Pamplona, Spania, 31008
- GSK Investigational Site
-
Santiago de Compostela, Spania, 15706
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand
- GSK Investigational Site
-
-
-
-
-
Brno, Tsjekkisk Republikk, 625 00
- GSK Investigational Site
-
Jihlava, Tsjekkisk Republikk, 586 01
- GSK Investigational Site
-
Olomouc, Tsjekkisk Republikk, 775 20
- GSK Investigational Site
-
Pardubice, Tsjekkisk Republikk, 532 03
- GSK Investigational Site
-
Praha 2, Tsjekkisk Republikk, 128 51
- GSK Investigational Site
-
Praha 5, Tsjekkisk Republikk, 150 08
- GSK Investigational Site
-
-
-
-
Baden-Wuerttemberg
-
Freiburg, Baden-Wuerttemberg, Tyskland, 79110
- GSK Investigational Site
-
-
Hessen
-
Marburg, Hessen, Tyskland, 35043
- GSK Investigational Site
-
-
Mecklenburg-Vorpommern
-
Neubrandenburg, Mecklenburg-Vorpommern, Tyskland, 17036
- GSK Investigational Site
-
Rostock, Mecklenburg-Vorpommern, Tyskland, 18059
- GSK Investigational Site
-
Schwerin, Mecklenburg-Vorpommern, Tyskland, 19055
- GSK Investigational Site
-
Wismar, Mecklenburg-Vorpommern, Tyskland, 23966
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Ludwigshafen, Rheinland-Pfalz, Tyskland, 67063
- GSK Investigational Site
-
-
Saarland
-
Homburg, Saarland, Tyskland, 66421
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Tyskland, 06120
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Tyskland, 24105
- GSK Investigational Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion criteria:
- History of PONV (postoperative nausea and vomiting) and/or motion sickness.
- Have not smoked for the last 6 months.
- Having certain abdominal, breast, thyroid or shoulder surgery.
Exclusion criteria:
- Pregnant or breastfeeding.
- Have certain pre-existing medical conditions or take certain medications.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants who achieved a complete response
Tidsramme: Up to 24 hours
|
Complete response defined as no vomiting or retching and no rescue therapy during the first 24 hours following placement of the last suture/staple.
Vomiting defined as the forceful expulsion of gastrointestinal contents through the mouth or nose.
Retching defined as the labored, spasmodic, rhythmic contraction of the respiratory and abdominal muscles in an attempt to vomit that is not productive of gastrointestinal contents (also known as "dry heaves").
Study participants who receive antiemetic rescue medication(s) during the initial 24 hours was considered treatment failures.
|
Up to 24 hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by an 11-point, linear, numerical rating scale referred to as a "0-10 Likert scale"
Tidsramme: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a Likert scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
The Likert scale used a range of 0-10, where 0 = no nausea and 10 = nausea as bad as it could be.
|
Up to 48 hours
|
|
The severity of nausea experienced by participants in each cohort during the 2, 6, 24 and 48 hour periods, as assessed by a categorical scale (none, mild, moderate or severe), as defined in the protocol
Tidsramme: Up to 48 hours
|
Nausea is defined as a subjectively unpleasant sensation associated with the awareness of the urge to vomit; the desire to vomit without the presence of expulsive muscular movements.
Each participant completed a categorical scale at 2, 6, 24 and 48 hours after placement of the last suture/staple.
In the categorical scale, each participant asked to rate the severity of nausea as, none: no nausea, mild: queasiness/upset stomach that is manageable and minimally (if at all) affects daily activities, moderate: increased queasiness, sometimes with the feeling of having to vomit (but not vomiting), that has a significant negative effect on daily activities (for example, being unable to work, eat and drink, prepare food, care for children or others), severe: feeling sick and vomiting or feeling like you are going to vomit, and unable to perform most daily activities.
|
Up to 48 hours
|
|
Number of participants with first emetic event
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with first antiemetic rescue medication
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant satisfaction with the prophylactic antiemetic regimens, as assessed by participant satisfaction assessments in the participant diary
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Participant willingness of participants to use the same treatment regimen for future surgical procedures, as assessed by participant satisfaction assessments in the participant diary
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with chemistry data outside the reference range
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Number of participants with hematology data outside the reference range
Tidsramme: Up to 48 hours
|
Up to 48 hours
|
|
|
Safety and tolerability of the antiemetic regimens, assessed by clinical observation (including time to awakening from anesthesia, defined as ability to respond to a verbal command)
Tidsramme: Up to 24 hours
|
Up to 24 hours
|
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: Up to Days 6-14 visit
|
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use.
The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.
Refer to the general AE/SAE module for a list of AEs and SAEs.
|
Up to Days 6-14 visit
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mars 2006
Primær fullføring (Faktiske)
1. juli 2006
Studiet fullført (Faktiske)
1. juli 2006
Datoer for studieregistrering
Først innsendt
2. juni 2006
Først innsendt som oppfylte QC-kriteriene
2. juni 2006
Først lagt ut (Anslag)
6. juni 2006
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
23. mars 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
21. mars 2017
Sist bekreftet
1. mars 2017
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Postoperative komplikasjoner
- Tegn og symptomer, fordøyelseskanal
- Kvalme
- Oppkast
- Postoperativ kvalme og oppkast
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Antiemetika
- Gastrointestinale midler
- Neurokinin-1-reseptorantagonister
- Kasopitant
Andre studie-ID-numre
- NKT102552
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Ja
IPD-planbeskrivelse
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Studiedata/dokumenter
-
Datasettspesifikasjon
Informasjonsidentifikator: NKT102552Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datasett for individuell deltaker
Informasjonsidentifikator: NKT102552Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotert saksrapportskjema
Informasjonsidentifikator: NKT102552Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Skjema for informert samtykke
Informasjonsidentifikator: NKT102552Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokoll
Informasjonsidentifikator: NKT102552Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk studierapport
Informasjonsidentifikator: NKT102552Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisk analyseplan
Informasjonsidentifikator: NKT102552Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .